Overview

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-30

Target enrollment:

Participant gender:

Summary

To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Treatments:

Irinotecan